An optimized antibody-single-chain TRAIL fusion protein for cancer therapy. - Wikidata - awgldk - TriplyDB

An optimized antibody-single-chain TRAIL fusion protein for cancer therapy.

An optimized antibody-single-chain TRAIL fusion protein for cancer therapy.

http://www.wikidata.org/entity/Q37141627

about

Antitumor Activity of a Mesenchymal Stem Cell Line Stably Secreting a Tumor-Targeted TNF-Related Apoptosis-Inducing Ligand Fusion Protein.Journey of TRAIL from Bench to Bedside and its Potential Role in Immuno-Oncology.Advancing targeted co-stimulation with antibody-fusion proteins by introducing TNF superfamily members in a single-chain format.IgG-single-chain TRAIL fusion proteins for tumour therapy.Targeting scFv-Fc-scTRAIL fusion proteins to tumor cells.A novel dual-cytokine-antibody fusion protein for the treatment of CD38-positive malignancies Duokines: a novel class of dual-acting co-stimulatory molecules acting in cis or trans

P2860

Q33658976-2A1479AB-C78F-467F-B2AA-D1774037DBC8 Q38557486-89138057-7E9F-4E27-853E-AA6BF0CDD886 Q41686962-499D34C2-164B-4B90-A2E0-5CE65C638A52 Q54998541-D8402BAA-406F-45A5-888B-751476D4EB79 Q55012569-3C56A6D3-36E7-4C5D-B61A-7C9F292D16E7 Q57201583-E52F3C63-3633-4860-A124-4328281980CF Q58804320-69356534-0C85-4374-BAE2-31AC701AF6F9

P2860

An optimized antibody-single-chain TRAIL fusion protein for cancer therapy.

http://www.wikidata.org/entity/Q37141627

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 11 April 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

An optimized antibody-single-chain TRAIL fusion protein for cancer therapy.

@en

An optimized antibody-single-chain TRAIL fusion protein for cancer therapy.

@nl

type

label

An optimized antibody-single-chain TRAIL fusion protein for cancer therapy.

@en

An optimized antibody-single-chain TRAIL fusion protein for cancer therapy.

@nl

prefLabel

An optimized antibody-single-chain TRAIL fusion protein for cancer therapy.

@en

An optimized antibody-single-chain TRAIL fusion protein for cancer therapy.

@nl

P1433

Q37141627-04233E61-8A43-4ED3-A1FA-650095A0F583

P1476

Q37141627-3D4BCA0F-0565-40EE-9ACA-7B7F400373F9

P2093

Q37141627-06BE211F-98CC-406D-8200-506F601F5925

Q37141627-0A6D4DAC-468E-4388-B1F7-2D2C795395A1

Q37141627-0DE9F8E6-E1F1-45C8-97EE-4042EC3EEEE3

Q37141627-31F92FDB-B2BD-42DC-8029-33C75EE8A2F9

Q37141627-61973E56-1CB5-4CED-BA94-EDBA7753DE99

Q37141627-6E7CE5D0-BDF7-4A4F-8E13-0A2C75D556E7

Q37141627-89458A98-F3D1-4985-8D09-23FADE567AC9

Q37141627-A82F0C98-78B4-49F2-AA61-41262A0267E3

Q37141627-B55A34DE-16BD-4E16-8E61-2980EEFE6889

P2860

Q37141627-07BEBEA5-0146-45C0-B976-104B0BE86E01

Q37141627-1E65245A-4663-4313-BE92-984FD23BBF41

Q37141627-246C0046-BCA3-45AA-AA11-BE18FD4C1C32

Q37141627-2F6B52DF-A63E-4652-8FBD-BBC0169D5C4A

Q37141627-3AA97E23-266C-49C5-8C04-FBFC577C7FF1

Q37141627-5383BD19-3280-4210-8EB1-ECC21E2DDA09

Q37141627-55E6DDD1-6EDA-4AC6-A266-E00957E3ED7D

Q37141627-5816C6DB-1376-4649-8842-ED983B56AD5E

Q37141627-6292556F-7342-4442-8F6B-8FDD7734A7DF

Q37141627-664A569E-F72B-46F2-9E96-7AA8780BEB4B

P304

Q37141627-8DAE59FF-F1C2-45A5-8080-962CE5CA26A0

P31

Q37141627-6CEBD088-DF43-4C5B-B1CF-1F32FDB3F36D

P356

Q37141627-DC359F3D-3EFF-41CC-9DDE-1897381882EE

P433

Q37141627-98CE983E-EDCB-4DCF-9AB8-5ED0D9B7DA9E

P478

Q37141627-16A0B9A1-FE82-48A1-9191-F2C5B2BD9E73

P50

Q37141627-06D90437-5255-44D9-A22B-137F70B5DF6A

P577

Q37141627-603A8CCC-0433-475B-86A9-0A9AE4DBE1FD

P698

Q37141627-22605F7A-4AD5-4C5A-935B-8FD0734E9B2D

P932

Q37141627-99A141BF-820E-4B0F-9B9D-2EF6FD80C3E5

P356

19420862.2016.1172163

P1433

Monoclonal Antibodies

P1476

An optimized antibody-single-chain TRAIL fusion protein for cancer therapy

@en

P2093

Doris Göttsch

http://www.w3.org/2001/XMLSchema#string

Klaus Pfizenmaier

http://www.w3.org/2001/XMLSchema#string

Maria Zarani

http://www.w3.org/2001/XMLSchema#string

Martin Siegemund

http://www.w3.org/2001/XMLSchema#string

Meike Hutt

http://www.w3.org/2001/XMLSchema#string

Oliver Seifert

http://www.w3.org/2001/XMLSchema#string

Roland E Kontermann

http://www.w3.org/2001/XMLSchema#string

Sabine Münkel

http://www.w3.org/2001/XMLSchema#string

Valentino De Leo

http://www.w3.org/2001/XMLSchema#string

P2860

Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5

2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity

A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL

Untangling the ErbB signalling network

Rational design and engineering of therapeutic proteins

Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity

Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer.

Tetravalent antibody-scTRAIL fusion proteins with improved properties.

Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer

New insights into apoptosis signaling by Apo2L/TRAIL.

P304

879-891

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/19420862.2016.1172163

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Tamara Džinić

P577

2016-04-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27064440

http://www.w3.org/2001/XMLSchema#string

P932

4968136

http://www.w3.org/2001/XMLSchema#string